Larvol Delta - Aprea-Therapeuticsannounced-the-conrmation-of-a-partial-response-PR-in-its-ongoing-ACESOT1051-trial-evaluating-APR1051-a-potent-and-selective-WEE1-kinase-inhibitor

APR-1051 - Aprea

https://www.globenewswire.com/news-release/2026/03/30/3264570/0/en/Aprea-Therapeutics-Highlights-Positive-Emerging-Clinical-Activity-for-WEE1-Inhibitor-APR-1051-with-a-Confirmed-Partial-Response-in-the-Ongoing-Phase-1-ACESOT-1051-Trial.html

Mar 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next